Financings in Brief: Integrated Surgical Systems:
This article was originally published in The Gray Sheet
Integrated Surgical Systems: Commences initial public offering of 1.5 mil. shares of common stock for $5 per share and 1.5 mil. redeemable common stock warrants to buy common shares for $6 each. The Sacramento, California-based company is developing products for image-guided, computer-controlled surgery. Its lead product is the Robodoc surgical assistant system, which is marketed in Europe and has been used for total hip replacement procedures in 425 patients, according to the firm. The Robodoc is pending approval in the U.S., ISS says. Rickel & Associates and Aegis Capital Corporation managed the offering....
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.